MedTrace Logo

Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy

NCT06377072 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 428

Last updated 2026-04-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Shenqi Sherong Pill in participants with Mild or Moderate Cervical Spondylotic Myelopathy (qi deficiency, blood stasis and kidney deficiency type) which based on placebo-control, providing a basis for drug registration.

Conditions

  • Cervical Spondylotic Myelopathy

Interventions

DRUG

Shenqi Sherong Pill

two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks

DRUG

Placebo

two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks

Sponsors & Collaborators

  • Shanghai Hutchison Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Bolai Chen, doctor · Guangdong Provincial Hospital of Traditional Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-11
Primary Completion
2026-01-14
Completion
2026-01-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06377072 on ClinicalTrials.gov